TRP 8802 delivers 75% breakthrough response in IBS
Filed with ASX · · 9 pages · English
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- TRP-8803 delivers repeatable, high-intensity effect
- FY25 R&D Tax Incentive received
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Australian Patent Secures TRP 8803 Platform to 2042
Later from Entropy Neurodynamics
- Entropy files new US patent for IBS program
- Entropy completes Cohort 1 dosing in BED trial
- DSMB Clears TRP 8803 to Advance to Cohort 2
- 100% Clinical improvement, 50% Remission in BED study
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics